Cytokinetics Incorporated (NASDAQ: CYTK) released topline results from the SEQUOIA-HCM Phase 3 trial of aficamten in patients with symptomatic obstructive
This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives. ACTON, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics,
- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed - - 70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy; Median Overall Survival in
Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced it has entered into a purchase agreement with Nestlé Health Science, a globally recognized leader in the field of nutritional science,
Preclinical data in four well-established preclinical models of pain associated with tissue inflammation and nerve injury demonstrate AV-101's robust effects similar to gabapentin but with a better side effect
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has received approval from the University of Miami to enroll patients for its first in human clinical
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of its senior management will host an investor call at 8:30 AM Eastern Time on Wednesday, December 27, 2023 to discuss the topline results from
Oncternal Therapeutics Inc (NASDAQ: ONCT) updated the status of a recent study involving a treatment for relapsed or refractory aggressive B-cell lymphoma, including patients who have failed
ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market size is